207_Combined course Presentations

The CD19 CAR T Cell Success Story for relapsed ALL and CLL

• Complete remission and long- term responses in up to 90% of acute lymphoblastic leukemia (ALL) patients ( both adult and pediatric) • And in > 50% of chronic lymphocytic leukemia (CLL) patients. • On target side effects include B cell aplasia and cytokine release syndrome.

Emily Whitehead

Maud et al, NEJM 2015 & Blood 20